Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   21:43
1,315 USD (-0,38%)
(-0,38%)   21:43

22 maart 2024 · Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference · Persbericht

5 maart 2024 · Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata · Persbericht

4 maart 2024 · Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results · Persbericht

4 maart 2024 · Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX · Persbericht

28 februari 2024 · Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference · Persbericht

27 februari 2024 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets · Persbericht

4 januari 2024 · Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA · Persbericht

12 december 2023 · Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting · Persbericht

7 november 2023 · Nektar Therapeutics Reports Third Quarter 2023 Financial Results · Persbericht

31 oktober 2023 · Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets · Persbericht

13 oktober 2023 · Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress · Persbericht

2 oktober 2023 · Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy · Persbericht

27 september 2023 · Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer · Persbericht

13 september 2023 · Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis · Persbericht

7 september 2023 · Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th · Persbericht

8 augustus 2023 · Nektar Therapeutics Reports Second Quarter 2023 Financial Results · Persbericht

7 augustus 2023 · Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company · Persbericht

2 augustus 2023 · Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets · Persbericht

13 juni 2023 · Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference · Persbericht

9 mei 2023 · Nektar Therapeutics Reports First Quarter 2023 Financial Results · Persbericht

Mijn selecties